IL37 and inflammatory bowel disease: Considering the data suggesting the crucial role of IL-23 in promoting the refractoriness of immune cells (mainly T cells and macrophages) to TNF inhibition, combining IFX with another monoclonal antibody interfering with IL-23-dependent pathways seems to be a promising therapeutic approach in IBD (19).